secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001193125-24-162652
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024
-----------------------------------------------------------------------

- Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.
- Ogden continues as Principal Accounting and Financial Officer, roles held since September 2022.
- Granted option to purchase 75,000 shares and RSU award for 17,500 shares under 2015 Equity Incentive Plan.
- No family relationships or arrangements with other parties in connection with his appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/0001193125-24-162652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/d831468d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-162652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer